Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/BridgeBio Pharma stock jumps 130% on optimism for ATTR-CM drug Attruby and pipeline progress
BBIO
$82.33
-$1.77 -2.10%

BridgeBio Pharma stock jumps 130% on optimism for ATTR-CM drug Attruby and pipeline progress

Analyst Insights
23 Apr 2026
Seeking Alpha
View Source
Bullish
pluang ai news

BridgeBio Pharma's stock has surged 130% since last year, reaching a $14.4 billion market cap driven by optimism around its ATTR-CM drug Attruby and pipeline developments. Attruby is expected to generate $362 million in sales by 2025 but faces competition from Pfizer and Alnylam, with potential generic threats ahead. The company reported a net loss of $725 million in 2025 on $502 million revenue, reflecting high R&D and SG&A expenses as it invests in expanding its pipeline. Upcoming catalysts include the BBP-418 drug for LGMD2I/R9 and two NDA submissions planned for 2026, which support the current valuation and future growth potential.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App